Program Description
Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF) that negatively impacts their quality of life and function and contributes significantly to hospitalizations. The likelihood of ID increases in patients living with advanced HF and during HF exacerbations, where rates may be as high as 75%. Screening for ID is a key strategy for its identification, and pharmacists should be aware of certain clinical features indicative of ID that may be present even in patients with HF with normal hemoglobin. This webinar will focus specifically on factors that inform the diagnosis of ID in HF, with a review of clinical guideline recommendations. Expert faculty will examine the role of intravenous iron formulations, considering dosing, administration, adverse event monitoring, and how guideline-directed treatment protocols can improve outcomes. This webinar is part of the Iron Deficiency Anemia Webinar series.
Target audience: Ambulatory Care Pharmacist, Community Pharmacist, Health System Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: June 11, 2025
Expiration date: June 11, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the risk factors, clinical signs, and diagnostic markers associated with iron deficiency in individuals diagnosed with heart failure (HF)
- Examine the latest clinical advancements and recommended guidelines regarding the utilization of intravenous iron in addressing iron deficiency (ID) among patients diagnosed with HF
- Apply best practices to improve screening and monitoring of ID in HF
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here